| Autor: |
Hamadani M; Division of Hematology and Oncology, BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI., Spira A; Virginia Cancer Specialists Research Institute, Fairfax, VA., Zhou X; RTI Health Solutions, Research Triangle Park, NC., Liao L; ADC Therapeutics America Inc, Murray Hill, NJ., Chen L; ADC Therapeutics America Inc, Murray Hill, NJ., Radford J; NIHR Clinical Research Facility, University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom., Ai W; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA., Solh M; Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA., Ardeshna KM; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Hess B; Department of Medicine, Medical University of South Carolina, Charleston, SC., Caimi PF; Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH., Stathis A; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland., Carlo-Stella C; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; Department of Oncology and Hematology, Humanitas Research Hospital-IRCCS, Milan, Italy., Alderuccio JP; Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL., Kahl B; Division of Oncology, Washington University, St. Louis, MO., Wang Y; ADC Therapeutics America Inc, Murray Hill, NJ., Qin Y; ADC Therapeutics America Inc, Murray Hill, NJ., Xu ZC; ADC Therapeutics America Inc, Murray Hill, NJ., Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy. |
